171 related articles for article (PubMed ID: 19906261)
1. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels.
Soares HD; Chen Y; Sabbagh M; Roher A; Schrijvers E; Breteler M
Ann N Y Acad Sci; 2009 Oct; 1180():56-67. PubMed ID: 19906261
[TBL] [Abstract][Full Text] [Related]
2. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease.
Choe LH; Dutt MJ; Relkin N; Lee KH
Electrophoresis; 2002 Jul; 23(14):2247-51. PubMed ID: 12210229
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.
Finehout EJ; Franck Z; Choe LH; Relkin N; Lee KH
Ann Neurol; 2007 Feb; 61(2):120-9. PubMed ID: 17167789
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.
Simonsen AH; McGuire J; Podust VN; Davies H; Minthon L; Skoog I; Andreasen N; Wallin A; Waldemar G; Blennow K
Neurobiol Aging; 2008 Jul; 29(7):961-8. PubMed ID: 17321007
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach.
D'Ascenzo M; Relkin NR; Lee KH
Curr Opin Mol Ther; 2005 Dec; 7(6):557-64. PubMed ID: 16372405
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Alzheimer's disease.
Sonnen JA; Keene CD; Montine KS; Li G; Peskind ER; Zhang J; Montine TJ
Expert Rev Neurother; 2007 Aug; 7(8):1021-8. PubMed ID: 17678497
[TBL] [Abstract][Full Text] [Related]
7. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia.
Simonsen AH; McGuire J; Podust VN; Hagnelius NO; Nilsson TK; Kapaki E; Vassilopoulos D; Waldemar G
Dement Geriatr Cogn Disord; 2007; 24(6):434-40. PubMed ID: 17971664
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
[TBL] [Abstract][Full Text] [Related]
9. Recent cerebrospinal fluid biomarker studies of Alzheimer's disease.
Choi YS; Choe LH; Lee KH
Expert Rev Proteomics; 2010 Dec; 7(6):919-29. PubMed ID: 21142892
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
11. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects.
Cedazo-Minguez A; Winblad B
Exp Gerontol; 2010 Jan; 45(1):5-14. PubMed ID: 19796673
[TBL] [Abstract][Full Text] [Related]
13. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
[TBL] [Abstract][Full Text] [Related]
15. Serum biomarkers for Alzheimer's disease: proteomic discovery.
German DC; Gurnani P; Nandi A; Garner HR; Fisher W; Diaz-Arrastia R; O'Suilleabhain P; Rosenblatt KP
Biomed Pharmacother; 2007 Aug; 61(7):383-9. PubMed ID: 17614251
[TBL] [Abstract][Full Text] [Related]
16. Proteome studies of CSF in AD patients.
Davidsson P; Sjögren M
Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296
[TBL] [Abstract][Full Text] [Related]
17. [Use of CSF biomarkers in the diagnostics of memory diseases].
Remes A; Leikola M; Majamaa K; Nikkanen M; Ruokonen LI; Rusanen M; Tapiola T; Ylikotila P; Vallittu AM; Pirttilä T
Duodecim; 2009; 125(20):2215-22. PubMed ID: 19998760
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
Blennow K
Expert Rev Mol Diagn; 2005 Sep; 5(5):661-72. PubMed ID: 16149870
[TBL] [Abstract][Full Text] [Related]
19. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.
Simonsen AH; McGuire J; Hansson O; Zetterberg H; Podust VN; Davies HA; Waldemar G; Minthon L; Blennow K
Arch Neurol; 2007 Mar; 64(3):366-70. PubMed ID: 17353378
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
